# Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

> **NCT02735707** · PHASE3 · RECRUITING · sponsor: **UMC Utrecht** · enrollment: 20000 (estimated)

## Conditions studied

- Community-acquired Pneumonia, Influenza, COVID-19

## Interventions

- **DRUG:** Ceftriaxone
- **DRUG:** Moxifloxacin or Levofloxacin
- **DRUG:** Piperacillin-tazobactam
- **DRUG:** Ceftaroline
- **DRUG:** Amoxicillin-clavulanate
- **DRUG:** Standard course macrolide
- **DRUG:** Extended course macrolide
- **OTHER:** No systemic corticosteroid
- **DRUG:** Fixed-duration Hydrocortisone
- **DRUG:** Shock-dependent hydrocortisone
- **DRUG:** Fixed-duration higher dose Hydrocortisone
- **OTHER:** No antiviral agent for influenza
- **DRUG:** Five-days oseltamivir
- **DRUG:** Ten-days oseltamivir
- **OTHER:** No antiviral agent for COVID-19
- **DRUG:** Lopinavir / Ritonavir
- **DRUG:** Hydroxychloroquine
- **DRUG:** Hydroxychloroquine + lopinavir/ritonavir
- **DRUG:** Ivermectin
- **OTHER:** No immune modulation for COVID-19

## Key facts

- **NCT ID:** NCT02735707
- **Lead sponsor:** UMC Utrecht
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2016-04-11
- **Primary completion:** 2026-02
- **Final completion:** 2028-02
- **Target enrollment:** 20000 (ESTIMATED)
- **Last updated:** 2024-07-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02735707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02735707, "Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02735707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*